Visser M, van Rooijen D M, Wolf J, Beckers L, Ohm M, de Jonge M I, Buisman A M, den Hartog G
Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.
Laboratory of Medical Immunology, Radboud university medical center, Nijmegen, The Netherlands.
NPJ Vaccines. 2025 Jun 5;10(1):115. doi: 10.1038/s41541-025-01180-3.
Adults aged 65 years and older are at increased risk for infectious diseases, including invasive meningococcal disease (IMD), yet data on meningococcal vaccine immunogenicity in this population remain limited. In this randomized clinical trial (CTIS: 2024-513640-29-00, 13-05-2024), 222 older adults (65-85 years) received a quadrivalent meningococcal conjugate vaccine (MenACWY-TT), with 104 adults receiving a booster dose one year later. Serum bactericidal activity (rSBA) and polysaccharide-specific IgG and IgM concentrations were assessed. One month post-primary vaccination, 91-98% of participants had protective rSBA titers (≥8). Booster vaccination transiently increased bactericidal responses, but titers returned to pre-booster values within a year for MenC, -W, and -Y. rSBA titers correlated stronger with IgM than IgG, particularly for MenW and -Y. Interestingly, IgM depletion markedly reduced rSBA titers, while IgG depletion had minimal impact. These findings highlight that MenACWY-TT vaccination elicits functional antibody responses in older adults, largely driven by IgM.
65岁及以上的成年人感染传染病的风险增加，包括侵袭性脑膜炎球菌病（IMD），但该人群中脑膜炎球菌疫苗免疫原性的数据仍然有限。在这项随机临床试验（CTIS：2024-513640-29-00，2024年5月13日）中，222名老年人（65-85岁）接种了四价脑膜炎球菌结合疫苗（MenACWY-TT），其中104名成年人在一年后接受了加强剂量。评估了血清杀菌活性（rSBA）以及多糖特异性IgG和IgM浓度。初次接种疫苗后一个月，91-98%的参与者具有保护性rSBA滴度（≥8）。加强接种疫苗短暂增加了杀菌反应，但对于C群、W群和Y群，滴度在一年内恢复到加强前的值。rSBA滴度与IgM的相关性比与IgG的相关性更强，尤其是对于W群和Y群。有趣的是，IgM耗竭显著降低了rSBA滴度，而IgG耗竭的影响最小。这些发现突出表明，MenACWY-TT疫苗接种在老年人中引发了功能性抗体反应，主要由IgM驱动。
